Despite a modest Q1 earnings per share of only NT$0.01, CHC Healthcare Group's General Manager, Ming-Lun Li, remains optimistic about the company's 2024 operations. Li revealed that the company has secured numerous equipment orders that are currently being installed. Additionally, sales of the Baxter Da Vinci surgical robot solutions are promising, and performance in the medical management services sector has rebounded since April. The rapid expansion of their FuKang Pharmacy chain, projected to reach 60 outlets by year-end, along with ongoing negotiations for their MRI linear accelerators and proton therapy systems with several hospitals, sets a positive trajectory. However, significant contributions from these will likely manifest next year. Li expects a progressive increase in revenue and profitability throughout the year, with full-year growth surpassing that of 2023.
Read more
